Oxalo is developing a first-in-class drug to treat primary and secondary hyperoxaluria, and resulting severe recurrent kidney stones. Using breakthrough microbiome research from UChicago, we directly target the biology of these diseases and can uniquely utilize the orphan drug pathway in clinical trials. The company is a Platinum Winner of MassChallenge, a Finalist of the New Venture Challenge accelerator and has received a $2.3M NIH grant.